ArticleLeukemia2016
PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.
Abstract readLetter
In one paragraph
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients.Annals of hematology · 2025Pooled it
- End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.Haematologica · 2018Trial
- Enhancing prognostic accuracy in PMBCL: semiquantitative analysis of interim PET/CT scans.Scientific reports · 2025Article
- Article
- Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.Hematology reports · 2025Review
- Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century.Annals of hematology · 2024Article
- PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?HemaSphere · 2023Article
- Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study.Journal of clinical medicine · 2023Article
- High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.Scientific reports · 2022Article
- Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2021Article
- Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.Cancer medicine · 2021Article
- Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.Annals of hematology · 2021Article
- Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.The oncologist · 2021Article
- Article
- Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.Cancer medicine · 2019Article
- Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.Bone marrow transplantation · 2018Article
- Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.Haematologica · 2018Article
- Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.European journal of nuclear medicine and molecular imaging · 2017Article
- Article
- Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.Leukemia · 2016Article
Corrections and comments
- Commented on by
Authors and funding
38 authors.
T P VassilakopoulosDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
G A PangalisDepartment of Haematology, Athens Medical Center, Psychikon Branch, Athens, Greece.
S ChatziioannouDepartment of Nuclear Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.
S PapageorgiouSecond Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece.
M K AngelopoulouDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Z GalaniThird Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.
G KourtiDepartment of Haematology and Lymphoma, Evangelismos General Hospital, Athens, Greece.
V PrassopoulosDepartment of Nuclear Medicine, HYGEIA Hospital, Athens, Greece.
T LeonidopoulouDepartment of Haematology, Sismanoglion General Hospital, Athens, Greece.
E TerposDepartment of Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
M N DimopoulouDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
S SachanasDepartment of Haematology, Athens Medical Center, Psychikon Branch, Athens, Greece.
C KalpadakisDepartment of Haematology, University of Crete, Iraklion, Greece.
P KonstantinidouDepartment of Haematology, Theagenion Anticancer General Hospital, Thessaloniki, Greece.
D BoutsisDepartment of Haematology, Athens Navy Hospital, Athens, Greece.
E StefanoudakiDepartment of Haematology, Amalia Fleming Hospital, Athens, Greece.
L KyriazopoulouDepartment of Haematology, University of Ioannina, Ioannina, Greece.
M P SiakantarisFirst Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
M-C KyrtsonisFirst Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
E VariamiFirst Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
I KotsianidisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
A SymeonidisHematology Division, Department of Internal Medicine, University of Patras, Patras, Greece.
E MichaliDepartment of Clinical Haematology, "G.Gennimatas" Athens General Hospital, Athens, Greece.
E KatodritouDepartment of Haematology, Theagenion Anticancer General Hospital, Thessaloniki, Greece.
G KokkiniDepartment of Haematology, Sismanoglion General Hospital, Athens, Greece.
C TsatalasDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
H PapadakiDepartment of Haematology, University of Crete, Iraklion, Greece.
M-A DimopoulosDepartment of Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
V SotiropoulosDepartment of Nuclear Medicine and PET/CT, Athens Medical Center, Athens, Greece.
V PappaSecond Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece.
T KarmirisDepartment of Haematology and Lymphoma, Evangelismos General Hospital, Athens, Greece.
J MeletisDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
J ApostolidisDepartment of Haematology and Lymphoma, Evangelismos General Hospital, Athens, Greece.
I DatserisDepartment of Nuclear Medicine and PET/CT, Evangelismos General Hospital, Athens, Greece.
P PanayiotidisFirst Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
K KonstantopoulosDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
P RoussouThird Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.
P RondogianniDepartment of Nuclear Medicine and PET/CT, Evangelismos General Hospital, Athens, Greece.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMediastinal NeoplasmsMiddle AgedPositron-Emission TomographyPrednisonePrognosisRituximabCyclophosphamideDoxorubicinPrednisoneRituximabVincristine
Identifiers
PMID
25971363What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.